pentoxifylline has been researched along with HIV-Associated Lipodystrophy Syndrome in 1 studies
HIV-Associated Lipodystrophy Syndrome: Defective metabolism leading to fat maldistribution in patients infected with HIV. The etiology appears to be multifactorial and probably involves some combination of infection-induced alterations in metabolism, direct effects of antiretroviral therapy, and patient-related factors.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lanzafame, M | 1 |
| Faggian, F | 1 |
| Lattuada, E | 1 |
| Antolini, D | 1 |
| Concia, E | 1 |
1 other study available for pentoxifylline and HIV-Associated Lipodystrophy Syndrome
| Article | Year |
|---|---|
[No improvement of lipodystrophy syndrome in an HIV-infected patient].
Topics: Adult; Antiretroviral Therapy, Highly Active; HIV Infections; HIV-Associated Lipodystrophy Syndrome; | 2004 |